XTL Biopharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference
01 November 2006 - 8:55PM
PR Newswire (US)
NEW YORK, November 1 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced
today that Ron Bentsur, the Company's Chief Executive Officer, is
scheduled to present at the Rodman & Renshaw 8th Annual
Healthcare Conference. Mr. Bentsur's presentation will take place
on Monday, November 6, 2006 at 10:15 am EST at the New York Palace
Hotel in New York City. A live webcast of Mr. Bentsur's
presentation will be available at
http://www.wsw.com/webcast/rrshq10/xtl.ln/. An archived version of
the webcast will be available following the conclusion of the live
presentation. ABOUT XTL BIOPHARMACEUTICALS LTD. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of infectious diseases, with a focus on hepatitis C. XTL is
developing XTL-2125 - a small molecule, non-nucleoside inhibitor of
the hepatitis C virus polymerase. XTL-2125 is currently in a Phase
1 clinical trial in patients with chronic hepatitis C. XTL is also
developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus - presently in Phase 1 clinical
trials in patients with chronic hepatitis C. XTL's hepatitis C
pipeline also includes several families of pre-clinical hepatitis C
small molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB)(LSE:XTL)(TASE:XTL).
Contact: Ron Bentsur, Chief Executive Officer Tel: +1-212-531-5960
DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact: Ron
Bentsur, Chief Executive Officer Tel: +1-212-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024